Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study — Giancarlo Comi (2010) | RDL Network
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
Article 2010 en
Authors
GC
Giancarlo Comi
OA
Oded Abramsky
TA
Txomin Arbizu
Abstract
1 min read
The good efficacy and the excellent safety and tolerability profiles of laquinimod 0.6 mg/day are confirmed in this extension study.
Gıancarlo Comı, Timothy R. Vollmer, Xavier Montalbán, Tjalf Ziemssen, Alexey Boyко, Patrick Vermersch, Tamar Rachmilewitz, Noah J. Sasson, Tali Gorfine, Volker Knappertz, Maria A. Rocca, Massimo Filippi
Discussion(0)
No comments yet. Be the first to comment.